RAS mutations predict lack of response to Vectibix

A new analysis published in The New England Journal of Medicine found that RAS mutations--beyond the understood KRAS exon 2 mutations--can be used to predict a lack of response to Vectibix plus the oxaliplatin-based chemotherapy FOLFOX. "While the KRAS exon 2 biomarker is well-known and has facilitated selection of patients more likely to respond to anti-EGFR treatment, we found that there were still some patients who didn't benefit from treatment," said Jean-Yves Douillard, a professor of medical oncology at the Centre René Gauducheau in France. "This analysis is important as it furthers our understanding of tumor genetics and allows physicians to more accurately match patients to effective treatments." Release